Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2023 07:40 ET | Source: HCW Biologics, Inc

HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan

Provides funding for buildout of new headquarters and manufacturing facility Capital requirements now funded into 2025 MIRAMAR, Fla., April 27, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the...
April 13, 2023 07:15 ET | Source: HCW Biologics, Inc

HCW Biologics Poster Presentation at AACR Annual Meeting 2023

Presentation of data for the mechanism underlying HCW9218 against solid tumors HCW9218 is the clinical-stage, lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., April 13, 2023 (GLOBE...
April 03, 2023 08:13 ET | Source: HCW Biologics, Inc

A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases

HCW Biologics Published a Pivotal Scientific Paper in Aging Cell Subcutaneous Administration of HCW9218 Systemically Reduces Senescent Cells and Alleviates Senescence-Associated Secretory Phenotype...
March 28, 2023 16:25 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights

MIRAMAR, Fla., March 28, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
December 08, 2022 07:55 ET | Source: HCW Biologics, Inc

HCW Biologics Enters CRADA with National Cancer Institute

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
December 07, 2022 07:30 ET | Source: HCW Biologics, Inc

HCW Biologics is Granted Second Fundamental Patent: U.S. Patent for Multi-Chain Chimeric Polypeptide Created with TOBI™ Platform

Allowed Claims for Novel Immunotherapeutic Compound Constructed with Tissue Factor as Platform for Target Binding Domains Patent for Underlying Intellectual Property for HCW9218 Currently in Clinical...
November 08, 2022 07:00 ET | Source: HCW Biologics, Inc

Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 in Solid Tumors At the SITC 37th Annual Meeting

Presentation includes data on safety and dosage escalationand immune system reaction to HCW9218 No incidence of mucosal bleeding resulting from the HCW9218 TGF-β trap HCW9218 is one of the lead...
November 07, 2022 16:45 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Third Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
August 12, 2022 07:00 ET | Source: HCW Biologics, Inc

HCW Biologics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

MIRAMAR, Fla., Aug. 12, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and...
August 03, 2022 07:15 ET | Source: HCW Biologics, Inc

U.S. Patent Issued to HCW Biologics for Foundational Platform Technology

MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel...